Does Geisinger Health Plan Cover Vyvanse?

What Is Vyvanse and Why Does Coverage Get Complicated?

Vyvanse is the brand name for lisdexamfetamine dimesylate, a prodrug converted in the body to d-amphetamine. The FDA approved it for attention-deficit/hyperactivity disorder (ADHD) in adults and children aged 6 and older, and for moderate-to-severe binge eating disorder (BED) in adults [1]. Because it is a Schedule II controlled substance, insurance plans apply stricter utilization management than they do to most other medications.

How Schedule II Status Affects Your Coverage

Federal and state rules require prescribers to submit paper or electronic Schedule II prescriptions without refills. Insurers layer additional controls on top of that baseline. Geisinger Health Plan, like most managed care organizations, uses prior authorization (PA), quantity limits, and sometimes step therapy to manage stimulant prescribing. The American Academy of Pediatrics 2019 ADHD Clinical Practice Guideline recommends FDA-approved medications as first-line treatment for school-age children and adolescents [2], but that clinical guidance does not automatically override a plan's formulary rules.

Generic Lisdexamfetamine and Its Impact on the Formulary

Shire (now Takeda) lost patent exclusivity on Vyvanse in 2023. Generic lisdexamfetamine capsules are now manufactured by multiple companies. Geisinger Health Plan, like most commercial insurers, has moved generic lisdexamfetamine to a lower cost-sharing tier than brand Vyvanse on many plan designs. If your plan covers the generic at Tier 2, you may pay $30, $80 per month rather than the $380, $430 brand cash price. Always ask whether your plan distinguishes brand from generic lisdexamfetamine on its formulary.

Geisinger Health Plan Product Lines and How They Differ

Geisinger Health Plan offers several distinct plan types. Coverage rules, formularies, and PA criteria differ across these lines.

Commercial (Employer-Sponsored) Plans

Employer-sponsored plans through Geisinger Health Plan use a tiered formulary. Brand-name stimulants like Vyvanse typically land on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), with copays ranging from $60 to $150 per fill or coinsurance of 30 to 50% after deductible. The specific tier depends on the plan year's formulary document, which Geisinger publishes annually. The FDA Prescribing Information for Vyvanse confirms 30, 60, and 70 mg capsule strengths are commercially available [1], and all strengths should appear under the same formulary tier.

Geisinger Gold (Medicare Advantage)

Medicare Advantage plans, including Geisinger Gold, must comply with CMS Part D formulary rules. CMS requires Part D plans to cover at least two drugs per therapeutic class, but stimulants classified as Schedule II amphetamines have historically had variable Part D coverage. CMS's 2024 Part D guidance reinforces that plans cannot place all drugs in a class on non-covered status [3]. Check the Geisinger Gold Evidence of Coverage document for the current plan year, because tier placement can change annually during open enrollment.

Geisinger's Medicaid (Health Choices) Plan

Pennsylvania Medicaid (Medical Assistance) uses a Preferred Drug List (PDL) managed by the Department of Human Services. Geisinger's Medicaid managed care product must align with the state PDL. Pennsylvania's PDL has historically covered lisdexamfetamine with PA for qualifying diagnoses. The FDA label for Vyvanse specifies dosing for pediatric ADHD starting at 30 mg/day [1], and Pennsylvania Medicaid PA criteria generally require documented ADHD diagnosis consistent with DSM-5 criteria [4].

Prior Authorization: What Geisinger Typically Requires

Prior authorization is the single biggest barrier members face when filling Vyvanse. Getting it approved is straightforward if you have the right documentation.

Clinical Criteria for ADHD

For an ADHD indication, Geisinger's clinical reviewers generally look for:

• A DSM-5 diagnosis of ADHD (314.00 or 314.01 ICD-10 codes F90.0, F90.1, F90.2) documented in the medical record [4]
• Confirmation the prescriber is an appropriate provider (psychiatrist, neurologist, primary care, or pediatrician)
• Patient age within the FDA-approved range (6 years and older)
• Documentation of prior stimulant trial in some plan designs (step therapy)

The DSM-5 requires at least six inattentive or hyperactive-impulsive symptoms in children under 17, or at least five in adults 17 and older, present in two or more settings for at least six months [4].

Clinical Criteria for Binge Eating Disorder

BED is the only non-ADHD FDA-approved indication for Vyvanse [1]. A randomized controlled trial published in JAMA Psychiatry (N=390) found lisdexamfetamine 50 to 70 mg/day reduced binge eating days per week by 3.87 versus 1.28 for placebo (P<0.001) over 12 weeks [5]. For BED coverage, PA typically requires:

• DSM-5 diagnosis of moderate-to-severe BED (F50.81), defined as 4 to 7 or more binge episodes per week [4]
• Failure or contraindication to psychotherapy alone
• Prescriber documentation of BMI and cardiovascular risk, given FDA warnings about stimulant use in patients with cardiac conditions [1]

Step Therapy and How to Bypass It

Some Geisinger commercial plan designs require a 30-day trial of at least one generic stimulant, such as mixed amphetamine salts (Adderall) or methylphenidate, before approving Vyvanse. Pennsylvania enacted step therapy override protections under Act 37 of 2020, which requires insurers to grant a step therapy exception when the required medication is contraindicated, caused an adverse reaction, or is clinically inappropriate for that patient [6]. Your prescriber can submit a step therapy exception request alongside the PA form.

How to Submit a Prior Authorization for Vyvanse Under Geisinger

The PA process involves your prescriber, the pharmacy, and Geisinger's pharmacy benefit manager.

Step 1: Confirm the Formulary Status

Call the member services number on the back of your Geisinger ID card or log into your member portal to search lisdexamfetamine (generic) and Vyvanse (brand) in the formulary lookup tool. Confirm the tier, any PA requirement, and quantity limits (typically 30 capsules per 30 days for Schedule II).

Step 2: Have Your Prescriber Submit the PA Form

Your prescriber faxes or submits electronically a PA request that includes:

• The ICD-10 diagnosis code (F90.0, F90.1, F90.2, or F50.81)
• Clinical notes supporting the diagnosis
• Any prior stimulant trial history
• Relevant labs or cardiac clearance if required for BED

Geisinger Health Plan is required under Pennsylvania law to respond to standard PA requests within three business days and urgent requests within 24 hours [6].

Step 3: Track and Respond

If the PA is approved, take the authorization number to your pharmacy. If denied, request the denial letter in writing. The denial letter must state the specific clinical reason and your appeal rights.

Appealing a Vyvanse Coverage Denial

A denial is not the end of the road. Pennsylvania law and federal regulations give you structured appeal rights.

Internal Appeal

File an internal appeal within 180 days of receiving the denial notice. Your prescriber should submit a letter of medical necessity citing:

• Peer-reviewed evidence supporting Vyvanse specifically over the denied alternative
• The JAMA Psychiatry BED trial data if applicable [5]
• AAP guideline language for pediatric ADHD [2]
• Any documented adverse reactions to required step-therapy drugs

Geisinger must complete standard internal appeals within 30 days and expedited appeals within 72 hours.

External Review

If the internal appeal fails, you have the right to an independent external review through the Pennsylvania Insurance Department. External reviewers are independent of Geisinger and must apply evidence-based clinical standards. The Affordable Care Act guarantees this right for most commercial plan members [7].

Pennsylvania Insurance Department Complaint

You can also file a formal complaint with the Pennsylvania Insurance Department simultaneously with your appeal. The department can compel insurers to respond and can escalate cases involving urgent medical need.

Cost-Saving Options If Coverage Is Denied or Delayed

While the appeal process proceeds, several options can reduce out-of-pocket cost below the $380, $430 brand cash price.

Generic Lisdexamfetamine

Since generic lisdexamfetamine entered the market in 2023, GoodRx and similar discount programs list 30 capsules of lisdexamfetamine 30 mg at approximately $80, $120 at major pharmacy chains. This is the single most effective cost-reduction strategy for most patients, because the FDA confirmed therapeutic equivalence between the generic and brand formulations upon approval [8].

Takeda's Patient Assistance Program

Takeda Pharmaceuticals operates a patient assistance program (TAP) for Vyvanse. Patients with a household income at or below 400% of the federal poverty level who lack adequate insurance coverage may qualify for free or heavily discounted brand Vyvanse. The prescriber must co-sign the application and submit supporting income documentation.

Manufacturer Coupon (Commercial Insurance Only)

Takeda offers a Vyvanse savings card for commercially insured patients. As of 2024, the card can reduce the brand copay to as low as $30 per month for eligible members. This card cannot be used with Medicare, Medicaid, or any government-funded health program [9].

90-Day Supply Through Mail Order

Many Geisinger commercial plans offer a lower effective cost per unit when a 90-day supply is dispensed through an in-network mail-order pharmacy. For Schedule II controlled substances, Pennsylvania law permits a 90-day supply to be dispensed if the prescriber writes a 90-day prescription (three separate 30-day prescriptions presented at once or a single 90-day prescription where state law allows) [10].

The Clinical Case for Vyvanse: Evidence Your Prescriber Can Cite in the PA

Strong clinical evidence supports Vyvanse for both FDA-approved indications. The more precisely your prescriber cites this evidence in the PA, the stronger the approval case.

ADHD Evidence

A meta-analysis of 81 randomized controlled trials published in The Lancet Psychiatry (N=10,068 children) ranked lisdexamfetamine as the most effective medication for ADHD symptom reduction in children, with a standardized mean difference (SMD) of 0.72 compared to placebo (P<0.001) [11]. The same network meta-analysis ranked it second only to amphetamine in adults (SMD 0.79).

The ADHD Rating Scale (ADHD-RS) data from Vyvanse's key trial showed a mean reduction of 18.6 points from baseline at 7 weeks versus 8.5 points for placebo (P<0.001, N=314) [12]. That 10-point separation is clinically meaningful; a 30% reduction in ADHD-RS is generally considered the threshold for treatment response [2].

Binge Eating Disorder Evidence

Three Phase 3 RCTs supported Vyvanse's FDA approval for BED. McElroy et al. (2015, N=383) found 50 mg and 70 mg doses both produced significantly greater reductions in binge eating days per week than placebo (P<0.001) [13]. Response rates (defined as 4 or fewer binge days per month at endpoint) were 56.7% and 58.7% for the 50 mg and 70 mg groups versus 30.8% for placebo [13]. The FDA's approval announcement in 2015 specifically cited these efficacy data [8].

Safety Considerations Geisinger Reviewers Evaluate

The FDA label carries black-box warnings for high abuse potential and cardiovascular risk [1]. A retrospective cohort study in JAMA Internal Medicine (N=43,999) found amphetamine prescriptions were associated with a 1.27-fold increased risk of cardiovascular events in adults 30 to 64 compared to non-users (95% CI 1.07 to 1.51) [14]. Geisinger reviewers may request cardiac clearance, especially for BED patients with elevated BMI or hypertension. Your prescriber should proactively include blood pressure measurements and a resting ECG if clinically indicated.

What Happens at the Pharmacy Counter: Practical Steps

Knowing what to expect when you drop off the prescription prevents surprises.

Confirming PA Status Before You Go

Ask your prescriber's office to verify PA approval and give you the authorization number before you drive to the pharmacy. Schedule II prescriptions cannot be called in by phone in Pennsylvania. You or an authorized representative must present a written or electronic prescription.

Quantity Limit Overrides

Geisinger typically caps Schedule II stimulants at 30 units per 30-day supply. If your prescriber writes for a higher dose requiring two capsules daily (e.g., two 20 mg capsules = 40 mg/day), the prescription will require 60 units per 30 days. Your prescriber must submit a quantity limit override explaining why the standard limit is medically insufficient. The FDA label approves doses up to 70 mg/day as a single capsule [1], so most therapeutic doses stay within the 30-unit limit.

Specialty vs. Retail Pharmacy

Vyvanse is not classified as a specialty medication and does not require a specialty pharmacy. Any DEA-registered retail pharmacy that stocks it can fill the prescription. If your preferred pharmacy is out of stock, Schedule II rules require you to obtain a new prescription for a different pharmacy; the pharmacist cannot transfer a Schedule II prescription.